- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kiana Mehring Discusses the Future of Value-Based Oncology Care
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.
Patient-reported outcomes are crucial to the future landscape of value-based oncology care and research models, says Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS).
Transcript
How do you see the future of value-based oncology care evolving, both within FCS and in the broader health care landscape?
One of the exciting things that value-based care has been moving toward in recent years is a patient-centric approach. The landscape is shifting to tailor treatments to individual patient needs, their preferences, outcomes, etc. Personalized medicine is certainly on the rise and patient engagement continues to be important.
I think another thing we're going to see in the coming years is more and more patient-reported outcomes. As we implement it into care models, that is really going to ensure that we're making our decisions, not without the patient included, but including the patient in the center of those decisions with the oncologist.
I also believe there's going to be a continued emphasis on early detection and preventative strategies that are going to reduce the need for those costly, late-stage treatments.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More
